RE: RE: RE: RE: Endo-Urocidin new study on refractJust went back to read all those posts. Still no answer to my question. I understand fully along the $ rationale for going after the refractory patients. But why do they plan to repeat the study in the PIIIb again. They already have the proof in the 105 patients study. (At least that;s how I understand what they were saying at the AGM, right...scrap the original first-line study planned as Piiib and get a new study on the refractory patients? )